Clarivate enhances off-x with pathway maps to accelerate target safety assessments

R&d teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights london , may 14, 2025 /prnewswire/ -- clarivate plc (nyse:clvt), a leading global provider of transformative intelligence, today announced the incorporation of pathway maps in off-x, a cutting-edge translational safety intelligence solution. with over 30% of drug development failures attributed to safety issues1, preclinical and translational research teams face increasing pressure to identify potential liabilities earlier in the target selection process.
CLVT Ratings Summary
CLVT Quant Ranking